FOLFIRI3-bevacizumab | ||
---|---|---|
(n = 61) | ||
Demographic or clinical characteristics | No. of patients | % |
Male | 35 | 57 |
Age, years | ||
Median | 63.6 | |
Range | 38-81 | |
ECOG performance status | ||
0 | 25 | 41 |
1 | 32 | 52 |
2 | 4 | 7 |
Primary tumor type | ||
Colon | 38 | 62 |
Rectal | 23 | 38 |
No. of sites involved by metastases | ||
1 | 35 | 57 |
2 | 19 | 31 |
> = 3 | 7 | 12 |
Site of metastatic disease | ||
Liver only | 25 | 41 |
Liver + other | 20 | 33 |
Other only | 16 | 26 |
Prior adjuvant chemotherapy | ||
All | 18 | 30 |
Oxaliplatin-based | 15 | 25 |
< 12 months | 8 | 13 |
Synchronous tumors | ||
Yes | 39 | 64 |
No | 22 | 36 |